RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics strengthens its scientific leadership by appointing renowned RNA interference expert Dr. Phillip Zamore to its Scientific Advisory Board, potentially boosting the company's cancer therapeutic research capabilities.
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading RNA interference (RNAi) researcher, to its Scientific Advisory Board. Dr. Zamore, who is currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, brings significant expertise in RNA biology and gene silencing mechanisms to the clinical-stage oncology company.
Zamore's distinguished scientific background includes co-founding Alnylam Pharmaceuticals and being elected to the National Academy of Sciences, highlighting his substantial contributions to the field of RNA research. His appointment signals a strategic enhancement to TransCode's RNA-targeted cancer therapy programs.
The company's primary focus is developing innovative treatments for metastatic diseases, with its lead therapeutic candidate TTX-MC138 targeting tumors that overexpress microRNA-10b. Zamore's expertise could potentially accelerate the development of TransCode's RNA therapeutic candidates and improve their ability to overcome current challenges in RNA delivery.
By recruiting a scientific luminary like Zamore, TransCode demonstrates its commitment to advancing cutting-edge cancer treatment technologies and leveraging top-tier scientific talent to drive potential breakthrough therapies.